Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 4/20 | 0.45 |
| ▸ | CETP | P11597 | 3/20 | 0.45 |
| ▸ | RXRB | P28702 | 3/20 | 0.45 |
| ▸ | RXRG | P48443 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21805836 | 0.85 | MEN1 (0.53) | NR4A2NR4A1NR4A3TSHRSRD5A2 | |
| Silver SCHEMBL4232127 | 0.84 | TSHR (0.50) | NR4A2NR4A1NR4A3TSHRKMT2A | |
| SCHEMBL5400948 | 0.84 | TSHR (0.61) | TSHRMEN1KMT2ACETPALDH1A1 | |
| SCHEMBL28488225 | 0.83 | NR4A1 (0.59) | NR4A2NR4A1NR4A3TSHRSRD5A2 | |
| SCHEMBL2981632 | 0.81 | NR4A1 (0.61) | NR4A2NR4A1NR4A3TSHRSRD5A2 | |
| SCHEMBL4220649 | 0.79 | NR4A2 (0.63) | NR4A2NR4A1NR4A3TSHRSRD5A2 | |
| SCHEMBL2207123 | 0.77 | MEN1 (0.50) | TSHRSRD5A2PLA2G4BMEN1KMT2A | |
| SCHEMBL2987983 | 0.77 | NR4A2 (0.65) | NR4A2NR4A1NR4A3TSHRSRD5A2 | |
| Terephthalic Acid SCHEMBL11039705 | 0.76 | NR4A2 (0.69) | NR4A2NR4A1NR4A3TSHRSRD5A2 | |
| SCHEMBL20710698 | 0.76 | LTA4H (0.52) | TSHRMEN1KMT2ACETPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572795-B2 | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090156555-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-18 | — | — | US | disclosed |
| EP-2001886-A2 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007103839-A2 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213300-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156555-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | CDK2, CDK3, CDK1 | NR4A2 2218/4885NR4A1 2433/4885NR4A3 1710/4885 |
| US-20070213300-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | CDK2, CDK3, CDK1 | NR4A2 2162/4885NR4A1 2402/4885NR4A3 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.